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Abstract
Introduction: The dynamic development of biobanks causes some ethical, social,
and legal problems. The most discussed problems are obtaining informed
consent, especially for future research, from minors and from deceased people.
The aim of this article is to present the current standards held by Polish biobanks
concerning obtaining a participant’s informed consent in some aspects.
Material and methods: Survey was carried out by anonymous questionnaire
among 59 institutions which deal with the collecting and storage of human cells
and tissues in the year 2008. Twenty four filled-in copies of the questionnaires
were sent back (return = 41%).
Results: Almost every institution (92%) obtains written consent, but a third of
the surveyed institutions (29%) do not obtain consent for the future use of the
samples. The majority of the respondents (83%) support the idea of using
biological materials for research purposes of a donor who died if he did not
leave any written objection to such practices and 46% of respondents stated
that biobanks should obtain the consent from the already mature donor who
gave their samples as a child.
Conclusions: The practice and rules for obtaining informed consent for the
scientific research require improvement. The possibility to use the human
materials in the future, conditions for getting access to the data, the possibility
of their withdrawal from the database and using the materials and data after
the death of the donor should be clearly determined when the informed consent
to collect the material is obtained.
Key words: biobanks, research ethics, informed consent, genetic collection
management.
Introduction
According to the definition provided by the Expert Group established
by the European Commission (EC), biobanks are various types of biological
sample sets, together with relevant databases [1]. They consist of private
and public organizations that store biological samples for clinical purposes
(genetic diagnosis, transfusion and transplantation), scientific research
(e.g. testing neurodegenerative diseases, monozygotic twins and isolated
populations) and criminal investigations (police biobanks) [2]. There are
many hopes connected with the development of biobanks: better
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recognition of genetic and environmental factors
of hereditary diseases, examination of the
susceptibility to specific diseases, personalised
medicine (adaptation of the treatment to the
patient’s individual genetic characteristics),
invention of new medicines and discovery of new
biomarkers.
The increasing number of biobanks in Europe
and worldwide requires integration and regulations.
A shortage of organisational relations between
biobanks and the difficult access to some of them
result in two situations: biobanks develop their own
set of rules applying to the collection, storage and
use of the collected material; and similar studies
are done in different institutions at the same time.
The collected samples are frequently not used after
the research project is finished and thus they are
destroyed (usually due to a shortage of funds
necessary to store them); hence, their scientific
potential remains unemployed [3]. Therefore, the
Expert Group of the EC insists on standardising
rules and practices that would facilitate sharing
data and samples for scientific purposes within the
territory of the European Union [1]. Last year the
OECD published Guidelines on Human Biobanks and
Genetic Research Databases [4]. It is also suggested
that an identification code – equivalent to the
International Standard Book Number (ISBN) – for
the biobanks should be introduced [3]. Despite the
fact that there are some biobank networks aiming
at research dedicated to specific diseases (e.g.
BrainNet), the most important European initiative
in the field is the BBMRI (Biobanking and
Biomolecular Resources Research Infrastructure)
project, in cooperation with the international
consortium P3G (The Public Population Project in
Genomics). As a matter of fact, relatively small
groups of participants are involved in many
population studies in Poland [e.g. 5, 6]. Stan  -
dardization of research rules in Polish biobanks and
joining in international initiatives could allow them
to conduct larger, multicentre studies.
The dynamic development of biobanks and
genetic research causes some ethical, social and
legal problems. Adequate solutions are needed in
order to guarantee a balance between the
innovative capacity of the scientific research and
the protection of the basic rights of the participants.
The Expert Group established by the EC and the
OECD guidelines underline the importance of
obtaining informed consent, of ensuring privacy
and of respecting the right to know and not to
know [1, 4]. The risk of discrimination caused by
genetic features and the possibility of commercial
use of the samples (samples of human cells and
tissues have become more valuable and are called
‘biovalue’) are among the commonly discussed
issues [7-10]. However, the most discussed problem
is the issue of informed consent. It is connected
with the following questions: access to the collected
material for scientists from other institutions;
consent to use biological samples in future scientific
research, using samples from donors who are now
dead, from minors or donors who are unable to
express any conscious consent; and the commer  -
cialization of research (e.g. gene patents). The public
trust in biobanks and genetic research depends
largely on whether these problems will be solved
properly.
The situation of Polish biobanks and the
standards of biological material storage are poorly
recognised. Such a situation hinders cooperation
between Polish biobanks and makes their incor  -
poration into the European biobanks network and
similar global institutions difficult. The first
information about some aspects of Polish biobanks
was our article published in the European Journal
of Public Health [11]. There has not been a serious
social debate on biobanks and genetic research in
Poland yet. Some regulations of the biobanks’
activity were added to the amended transplantation
act of 2005: the National Centre for Tissue and Cell
Banking was established and the requirement of
accreditation for all institutions of the field was
introduced [12]. However, it is uncertain to what
extent these regulations have been implemented
and there are still some issues that have not yet
been introduced. These issues include consent for
future research, other institution representatives’
access to the data, and the problem of the sample
encoding method.
In the light of all the above-mentioned issues,
we decided to gain relevant data on Polish
biobanks’ activity and gather biobanks’ managers’
opinions on problems connected with obtaining
informed consent. We have focused mostly on
issues related to consent to future research, from
minors and using biological material after the death
of the donors. Studies on biobanks conducted in
other European countries were based on similar
assumptions [13].
Material and methods
The anonymous questionnaire was sent (by mail)
to the directors of 59 institutions which deal with
the collection and storage of human cells and
tissues. It was sent to different types of biobanks:
umbilical cord blood banks (9), Regional Centres for
Blood Donation and Haemotherapy (22), hospital
blood and tissue banks (10), molecular diagnosis
laboratories associated with The Polish Society of
Human Genetics (9) and tissue banks associated
with the Poltransplant network (9). There is no
official Polish database containing all biobanks, so
the addresses were found on the Internet on the
following websites: the National Centre for Tissue
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and Cell Banking (www.kcbtik.pl), Poltransplant
(www.poltransplant.org.pl), the Polish Society of
Human Genetics (www.ibb.waw.pl), the National
Blood Centre (www.nck.gov.pl) and other websites
connected with healthcare and genetic research in
Poland. Together with the questionnaires, stamps
and envelopes (with a return address) were sent.
The survey was conducted from March to June
2008. 
The questions in the questionnaire focused
mainly on the following issues: informed consent
(the way the information is provided, obtaining
consent to use the biological material in the future),
respect for privacy (the anonymity of the stored
data, the method of coding, accessibility) and
observance of the right to know and not to know.
The respondents were also asked to suggest the
best solution to a situation where the research
institution desires to use the biological samples
collected from a donor who has already died or
from a child who has already become an adult.
Results
Twenty-four filled-in copies of the questionnaires
out of 59 sent to biobanks were sent back (return
= 41%). All received questionnaires were filled in
completely. The level of return was lowered by well-
known causes (outdated addresses, liquidation of
biobank; it relates to 18% of non-respondents) and
could have been lowered by unknown factors, such
as reluctance to cooperate or fear of revealing the
data. Some of the institutions voluntarily revealed
the data enabling their identification, but in the
majority of cases it was not known because the
questionnaire was anonymous.
Written consent for scientific use of materials is
obtained in almost every institution (92%, n = 22);
the rest of them obtain oral consent. However, only
in 54% of the requested biobanks (n = 13) is it
possible for a donor to talk to an expert before
donating, and the information leaflets for the
participants are available in 29% of the institutions
(n = 7). Almost one third of the surveyed biobanks
(29%, n = 7) do not acquire consent for future use
of the samples. A quarter of the respondents (25%,
n = 6) stated that a patient does not have the right
not to know the test results. 
The respondents were also asked about scientific
use of biological material from a donor who is no
longer alive and from an adult whose samples were
taken when he was a child, with the consent of his
parents. In the first case, the majority of the
respondents (83%, n = 20) supported the idea of
using the samples of the donor who has died if he
did not leave any written objection to such practices
before his death. In the second case, the
respondents’ opinions were very diverse: 46% 
(n = 11) of them stated that written or at least
electronic consent from the already mature donor
should be obtained, 38% (n = 9) indicated the
possibility of using the material on the basis of the
previous parents’ consent, and the rest of the
respondents indicated that the donor should be
informed in writing and in the case of lack of his or
her objection the sample could be used.
Discussion
The most frequently discussed ethical issue
associated with biobanks’ activity is the method of
providing information and obtaining informed
consent for scientific research, especially for future
scientific research. The practice of obtaining written
consent is observed in 92% of the surveyed
institutions, but a serious problem is that 8% of
biobanks obtain only oral consent (an oral form is
incorrect in this case). Other European countries
have a similar problem [13]. The results of our
survey also indicate that the way of providing
information in many Polish biobanks does not meet
the international requirements (the lack of written
information and the lack of the possibility to consult
an expert). The Expert Group of the EC and the
OECD recommend obtaining written consent from
a donor during a direct discussion, preceded by
a reading of the written informational leaflet [1, 4].
This procedure results from the fact that
information expressed in speech is more direct and
allows additional explanations to be given; however,
it can also be incomplete or it can be used to exert
an influence on the interlocutor. Printed
information, on the other hand, even if it can be
more complete, gives no guarantee that it is well
understood. Additionally, it should be mentioned
that according to the EU directive (95/46/EC),
individuals who donate samples for the research
should not only understand what collecting the
material involves and what kind of risk is related to
it but should also be provided with information on
the purposes of the samples’ usage [14]. Similarly,
the European Biomedical Convention (Convention
for the Protection of Human Rights and Dignity of
the Human Being with regard to the Application of
Biology and Medicine: Convention on Human Rights
and Biomedicine) emphasises in article no. 22 that
human tissues as well as cells isolated from the
human organism can only be used for purposes
they were collected for and within the area of use
defined by the donor’s consent.
An unfavourable phenomenon is that quite
a high percentage (28%) of the surveyed
institutions do not obtain consent to use samples
in future scientific research. It hinders conducting
research on the samples and it shows a lack of
awareness of the fact that the samples could be
used some other time or the lack of far-reaching
plans for operation. However, a survey conducted
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in six Western European countries demonstrated
that consent for future scientific use is rarely
obtained in biobanks in those countries as well [13]. 
Obtaining donor consent for the future use of
samples in scientific research provokes the biggest
disputes and doubts. The restrictive attitude to the
informed consent requirements would demand
frequent asking about the use of previously
collected data, which could prove to be very
disturbing and could discourage researchers from
conducting studies and donors from participating
in them. Because of that, different possible
solutions to this problem were suggested. For
example, the International Bioethics Committee of
UNESCO, WHO and some authors suggest a blanket
consent to possible future scientific research [7, 15,
16], others a presumed consent with opt-out [17-
19]. Some suggest not demanding distinct consent
before each study if the law guarantees access to
the data only to the researchers, the samples are
anonymous and the rules of collecting and storing
the tissues are under social control [20]. However,
it seems that such a form does not meet the
conditions of informed consent, because it does not
protect the donors’ interests [21]. CIOMS (the
Council for International Organizations of Medical
Sciences) believes that in cases of minimal risk the
ethical commission can waive the requirement of
obtaining informed consent for successive research
(it is the so-called waived consent) [22]. As a matter
of fact, in public opinion polls a significant
percentage of the respondents supported the
requirement of obtaining consent before each
successive study conducted on the samples – e.g.
it is 22% in Sweden, 29% in the US and over 50%
in the UK [19, 23, 24]. Caulfield et al. suggested an
authorisation model that would make it possible to
define what usage of the samples the donors do
not accept or in what circumstances they demand
to be asked to express distinct consent (e.g. in the
case of a study that has clinical significance for the
donor or when the research is to be commercially
used) [18] On the other hand, the First Genetic
Trust, an American biotechnological concern,
worked out a procedure of  dynamic consent by
sending the donors electronic information on the
use of their samples before each successive study
[25]. The European Society of Human Genetics
suggested diversifying the rules of informed
consent: if an existing collection consists of
encoded samples with no possibility of identifying
the donor (the so-called “anonymised collection”),
it is allowed to use them without obtaining new
consent. However, if identification of the donor is
possible (“identifiable collection”), the researchers
should apply to obtain consent and if it appears to
be impossible, the decision should be made by the
bioethics committee. Consent is always required in
the case of creating new collections of biological
material [26].
An essential issue connected with informed
consent in genetic tests is the right not to know. It
results from the domination of prognostic genetic
tests that allow one to detect rare monogenic
diseases for which there is a lack of an effective
method of treatment and the awareness of being
ill is a psychological burden for the patient. The
survey reveals the disturbing fact that a consi  -
derable percentage of Polish institutions (38%)
dealing with genetic tests do not respect the
patient’s right not to know. It might be a result of
a low level of knowledge of this law among Polish
society as well as among the workers and
managers of the biobanks. Respecting the law can
be especially important in the case of children, e.g.
in the case of Huntington disease it can be stated
that knowledge about some threats related to
disease progression strongly limits the development
of the sick children [27]. 
The cases of the use of samples recovered from
a donor who has died and from an adult whose
samples were taken when he was a child with the
consent of his parents are discussed in ethical
literature [28, 29]. The majority of countries have
approved the standard of presumed consent in
cases of samples from a donor who has died. That
is consistent with the Expert Group of EC
recommendations [1]. In the case of samples
collected from children, the solutions vary, e.g. in
France there is a standard of providing information
to now mature donors about the use of samples in
a study [30]. Polish respondents’ opinions are
generally consistent with the Expert Group of EC
recommendations. It should also be mentioned that
in the case of research on children, the risk of
trauma increases and obtaining informed consent
is more difficult. It seems fair to qualify for such
research only children over 7 years old when
expected improvements in their health will be
significant and can be obtained only through
scientific research [31].
It is becoming apparent that the amendment of
the Polish Transplantation Act from 2005 does not
sufficiently regulate Polish biobanks’ activity and
does not lead to its integration. It should be stated
that the chance to use the samples in the future,
conditions for getting access to the data, the
possibility of their withdrawal from the database
and using the materials and data after the death
should be clearly determined in a preliminary
contract or when consent to collect the material is
obtained. It should favour an increase in public trust
in biobanks and minimise the risk of potential
conflicts.
There are some limitations of our study. The
return rate is low (41%) and it is possible that not
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all biobanks were included because there is no
official Polish database for all biobanks. However,
these results allow us to reach some important
conclusions.  
In conclusion, some rules in the process of
obtaining informed consent in Polish biobanks
should be improved: obtaining consent for the
future use of samples in scientific research, the
possibility to talk with an expert before donating,
respecting the right not to know and the
requirement of obtaining consent in a written form
should be obeyed in all institutions. Biological
materials of deceased persons should be used for
research purposes if a donor who died did not leave
any written objection to such practices.
The current biobanks’ procedures in obtaining
informed consent do not differ to a relevant degree
from procedures applied in Western European
countries, and many Polish organisations can
cooperate with foreign institutions.
The possibility to use human materials in the
future, conditions for getting access to the data,
the possibility of their withdrawal from the
database and using the materials and data after
the death of the donor should be clearly
determined when the consent is obtained and the
sample is given. The consistency and transparency
of biobanks’ activity rules should promote public
trust and minimise the possibility of conflicts
between donors and biobanks.
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